Fair Price Device Act

HR 5158, the Fair Price Device Act, amends drug approval rules to require generic drug manufacturers to provide specific evidence when their drug is intended for use with a medical device. It directly affects pharmaceutical companies seeking approval for generic drugs that must be used with a device (like insulin pumps or inhalers). The key provision adds new requirements for applicants to submit comparative data on device compatibility, user interface differences, and human factors studies to prove the generic drug will perform equivalently to the brand-name version when used with the device. This ensures safety and effectiveness are maintained despite potential device variations, without changing the core approval standards for generic drugs.